ProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and Tolerability

/PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces positive preliminary results from the Phase I ProstACT SELECT...

Related Keywords

New York ,United States ,Australia ,Switzerland ,United Kingdom ,Belgium ,Brazil ,Melbourne ,Victoria ,Japan ,Canada ,Australian ,Colin Hayward ,Kyahn Williamson ,Nat Lenzo ,Scottt Tagawa ,Health Canada ,Australian Securities Exchange ,Australian Therapeutic Goods Administration ,Prnewswire Telix Pharmaceuticals Limited ,Drug Administration ,Telix Pharmaceuticals ,Telix Pharmaceuticals Limited Disclosure Committee ,European Union ,Genesiscare Group Clinical ,Corporate Communications ,Pharmaceuticals Limited ,Genesiscare Group Clinical Director Theranostics ,Telix Chief Medical Officer ,Marketing Authorisation Applications ,Telix Pharmaceuticals Limited ,